Concepedia

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease

Robert N. Baldassano, Christian Braegger, Johanna C. Escher, Kimberly L. DeWoody, David F. Hendricks, Gregory F. Keenan, Harland S. Winter

The American Journal of Gastroenterology · 2003 · 182 citations · 13 references

DOI

Abstract

The results of this trial suggest that infliximab may be safe and effective as short-term therapy of medically refractory moderate to severe CD in a pediatric population.

References

13

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine · 1997 · 3.1K citations · Full text

Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

Daniel H. Present, Paul Rutgeerts, Stephan Targan et al. · New England Journal of Medicine · 1999 · 2.7K citations · Full text

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

Vincent Kindler, André‐Pascal Sappino, Georges E. Grau et al. · Cell · 1989 · 1.3K citations

, , +9

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)

Hendrik M. van Dullemen, Sander J. H. van Deventer, Daan W. Hommes et al. · Gastroenterology · 1995 · 1.1K citations

, , +6

Development and Validation of a Pediatric Crohnʼs Disease Activity Index

Jeffrey S. Hyams, George D. Ferry, Francine S. Mandel et al. · Journal of Pediatric Gastroenterology and Nutrition · 1991 · 964 citations